|

Sunitinib Clinical Trials

11 actively recruiting trials across 6 locations

Also known as: SU11248, Sunitinib Malate, Sutent

Other4 trials

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Phase 2
Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors
Phase 1/2
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
Phase 1/2
The Drug Rediscovery Protocol (DRUP Trial)
Phase 2

Birmingham, Alabama2 trials

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

University of Alabama at Birmingham Cancer Center

Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

University of Alabama at Birmingham Comprehensive Cancer Center

Phase 2

Huntsville, Alabama1 trial

Pan Tumor Rollover Study

Local Institution - 0220

Phase 2

Phoenix, Arizona1 trial

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Research Facility

Phase 3

Los Angeles, California1 trial

Losartan + Sunitinib in Treatment of Osteosarcoma

Children's Hospital Los Angeles

Phase 1

Miami, Florida1 trial

ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST

University of Miami

Phase 2

Boston, Massachusetts1 trial

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

GSK Investigational Site

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.